No Detail Found!

Efficacy of Oral Methotrexate in the treatment of Plaque Psoriasis in a local population

Author(s)
Attiya Tareen Dermatology Department, Fauji Foundation Hospital,Rawalpindi,Pakistan
Sohaib Asghar Dermatology Department, Fauji Foundation Hospital,Rawalpindi,Pakistan
Uzma Rajar Professor, Dermatology Department, Isra University Hyderabad,,Pakistan
Hadia Yaqub Khan MBBS, Final Year Student, Shifa College of Medicine,Islamabad,Pakistan
Dujanah Bhatti Dermatology Department, Fauji Foundation Hospital,Rawalpindi,Pakistan
Maryam Asad Dermatology Department, Fauji Foundation Hospital,Rawalpindi,Pakistan
Abstract
To determine the safety and efficacy of methotrexate in treating plaque psoriasis.Methods: The interventional descriptive single-arm pre and post-study was conducted in the department of dermatologyFauji Foundation Hospital Rawalpindi from August 2018 to January 2021. This research was approved by the ethical reviewcommittee of the hospital. One hundred forty two patients between 15 to 60 years of age suffering from plaque typepsoriasis with PASI score of >8 were included in the study after taking the informed consent. Oral methotrexate in a dose of10 mg/week was given for 8 weeks to patients from dermatology outdoor and Indoor. (PASI 6 or greater).Baseline bloodcounts, blood urea nitrogen, serum creatinine, electrolytes, alkaline phosphatase, alanine aminotransferase and chest Xrayto rule out latent tuberculosis. They all got cured through a methotrexate dosage of 10mg that was adjusted between 5 mgto 25 mg based on individual conditions. Outcomes were measured as Psoriasis Area Severity Index PASI and Disease Activity Score DAS 28 for patients having psoriatic arthritis.Results: Of all the participants 116(81.1%) were female and 26 (18.2%) were male whereas mean age of participants was41.6 years. The mean pretreatment and post treatment PASI score shows significant drop from baseline (13.01+6.02) to eight weeks post treatment (5.4+3.2) which is statistically significant (P=<0.05). The change in percentage of PASI frombaseline was analyzed by the Wilcoxon signed ranks test after 8 weeks (t=17.29) ie PASI 75 was achieved in more than 50%of participants. There was a marked improvement in the DAS28 score of participants having Psoriatic arthritis. RegardingPsoriatic arthritis, Table 6 shows that 26 out of 29 (96.29%) patients had moderate Psoriatic arthritis with DAS 28 score ofless than 5 while 1(3.7%) patient had mild and 2(7.4%) had severe joint disease of greater than 5.1 DAS 28 score beforemethotrexate treatment. However majority ie 17/29 (62.9%) achieved complete remission in joint disease after 8 weeks ofmethotrexate treatment while a small number 2/29 (7.4%) still had DAS 28 score of up to 5.1 or moderate remission whilenone had high score of DAS28 of greater than 5.1 after 8 weeks.Conclusion: The outcome of this study has shown that the effective way to treat plaque psoriasis is through methotrexatewhich is efficient in treating coexisting psoriatic arthritis which is one of the important comorbidities associated with plaquepsoriasis
Publication Details
Page(s) 52-57
DOI DOI not available
Published Journal: BMC journal of Medical Sciences, Volume: 4, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Plaque psoriasis, Methotrexate, coexisting psoriatic arthritis, erythematous plaque
0

Citations

0

Downloads

67

Views